• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by T2 Biosystems Inc.

    8/15/24 8:24:37 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care
    Get the next $TTOO alert in real time by email
    SC 13G/A 1 sc13ga110871ttoob_08152024.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    T2 Biosystems, Inc.

     (Name of Issuer)

    Common Stock, par value $0.001 per share

     (Title of Class of Securities)

    89853L302

     (CUSIP Number)

    April 12, 2024

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 89853L302

     

      1   NAME OF REPORTING PERSON  
             
            JACOB SAFIER  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         755,000  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         -0-  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              755,000  
        8   SHARED DISPOSITIVE POWER  
               
              -0-  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            755,000  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.3%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    2

    CUSIP No. 89853L302

      1   NAME OF REPORTING PERSON  
             
            NEW DIMENSIONS TRADING LTD.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         755,000  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         -0-  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              755,000  
        8   SHARED DISPOSITIVE POWER  
               
              -0-  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            755,000  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.3%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 89853L302

    Item 1(a).Name of Issuer:

    T2 Biosystems, Inc. (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    101 Hartwell Ave.

    Lexington, MA 02421

     

    Item 2(a).Name of Person Filing:
    Item 2(b).Address of Principal Business Office or, if None, Residence:
    Item 2(c).Citizenship:

    New Dimensions Trading Ltd. (“New Dimensions”)
    c/o The Wolfson Group
    One State Street Plaza, 29th Floor
    New York, NY 10004
    Citizenship: Cayman Islands

    Jacob Safier
    c/o The Wolfson Group
    One State Street Plaza, 29th Floor
    New York, NY 10004
    Citizenship: United States

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    Item 2(d).Title of Class of Securities:

    Common Stock, par value $0.01 per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

    89853L302

     

    4

    CUSIP No. 89853L302

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership.
    (a)Amount beneficially owned:

     

    As of the date hereof:

    New Dimensions Trading Ltd. beneficially owned 755,000 Shares.

    Jacob Safier, as the portfolio manager of the T2 Biosystems, Inc. investment by New Dimensions, may be deemed to beneficially own the Shares owned by New Dimensions and, therefore, may be deemed to beneficially own 755,000 Shares. 

    (b)Percent of class:

     

    As of the date hereof, New Dimensions beneficially owned and Jacob Safier may be deemed to beneficially own 4.3% (based upon 17,479,954 Shares outstanding, which is the number of Shares reported as outstanding in the Issuer’s Quarterly Statement on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024). 

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

    5

    CUSIP No. 89853L302

    (ii)Shared power to vote or to direct the vote:

     

    0 Shares.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

    (iv)Shared power to dispose or to direct the disposition of:

     

    0 Shares.

     

    Item 5.Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [x].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.Certifications.

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    7

    CUSIP No. 89853L302

    SIGNATURE

     

    After reasonable inquiry and to the best of his or her knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: August 15, 2024

     

      New Dimensions Trading Ltd.
       
      By:

    /s/ Chana Edelstein

        Name: Chana Edelstein
        Title: Director

     

     

     

    /s/ Jacob Safier

      Jacob Safier

     

    8

     

    Get the next $TTOO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTOO

    DatePrice TargetRatingAnalyst
    2/18/2022$0.70Neutral → Buy
    Alliance Global Partners
    More analyst ratings

    $TTOO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/14/24 3:38:45 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/6/24 9:02:19 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/6/24 9:01:48 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

      LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.Executed contracts for 27 T2Dx® Instruments in 2024, including

      1/7/25 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

      LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel. The target hospitals for the new instruments include: Selling a second T2Dx Instrument to a major reference hospital to expand "same st

      12/18/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

      LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company's direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems' sepsis tests to blood culture-based diagnostics, and showed that T2 Biosystems' products provided: faster time to detection (e.g., species identification 77 hours faster), faster targeted therapy (

      12/17/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Liebman Seymour

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:58:44 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Giffin Brett A.

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:55:13 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Adams Laura Lee

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:46:12 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Financials

    Live finance-specific insights

    See more
    • T2 Biosystems Announces Third Quarter 2024 Financial Results

      LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar

      11/14/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

      LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320

      11/5/24 8:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Host Business Update Call on October 10, 2024

      LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the

      10/8/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • T2 Biosystems upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded T2 Biosystems from Neutral to Buy and set a new price target of $0.70

      2/18/22 10:16:52 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners resumed coverage on T2 Biosystems with a new price target

      Alliance Global Partners resumed coverage of T2 Biosystems with a rating of Neutral and set a new price target of $1.65 from $2.40 previously

      3/5/21 7:31:44 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems downgraded by Alliance Global Partners with a new price target

      Alliance Global Partners downgraded T2 Biosystems from Buy to Neutral and set a new price target of $2.40 from $2.60 previously

      1/27/21 8:12:03 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    Leadership Updates

    Live Leadership Updates

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer

      LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Mr. Giffin will join the Company's executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Mr. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S. "We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer," said John Sperzel, Chairman and CEO at T2

      11/4/21 4:04:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Appoints Laura Adams to Its Board of Directors

      LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately. "We are excited to have Laura join the T2 Biosystems Board of Directors," said John Sperzel, Chairman and CEO at T2 Biosystems. "Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory." Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing lead

      10/19/21 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $TTOO
    SEC Filings

    See more
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/4/25 5:47:15 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by T2 Biosystems Inc.

      NT 10-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/1/25 9:00:30 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      2/20/25 9:00:24 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care